Search Results
Sep 08, 2026, 09:05 ET Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp
Sep 08, 2026, 09:00 ET Global Genes Partners with Citizen Health to Power RARE-X
Global Genes' RARE Drug Development Symposium in Boston.
More news about: Global Genes
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients."Following the U.S. Food and Drug Administration (FDA) approval of IMDELLTRA for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy, the robust
More news about: Amgen
Sep 08, 2026, 08:48 ET AllyGPO Named to Fast Company's 2026 List of Best Workplaces for Innovators
purpose-built to optimize specialty drug management. The comprehensive platform combines smart inventory and contract management with on-demand, predictive practice intelligence — simplifying the complexity of buy-and-bill to help independent practices improve drug utilization and economics. AllyIQ integrates
More news about: AllyGPO
Sep 08, 2026, 08:20 ET Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals
More news about: Accro Bioscience (Suzhou) Limited
Sep 08, 2026, 08:17 ET HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
withdrawals, or discontinuations; adverse events were balanced between active arms and placebo, with low rates of injection site reactions and anti-drug antibodies. The first Phase 3 study of HBM9378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is
More news about: Harbour BioMed
Sep 08, 2026, 08:05 ET Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease.
More news about: Alebund Pharmaceuticals
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects,
More news about: Kelun-Biotech
Sep 08, 2026, 08:00 ET Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
agencies, including Breakthrough Therapy Designation and Fast Track Designation from the US Food and Drug Administration; Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products Administration; access granted to the European
More news about: Sanofi
Sep 08, 2026, 08:00 ET Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program.Genprex's preclinical diabetes program is
More news about: Genprex, Inc.
Sep 08, 2026, 08:00 ET Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO")
More news about: Intensity Therapeutics Inc.
Sep 08, 2026, 08:00 ET Peptide Tracker Rolls Out Major Update Wave: Split Dosing, Custom Compound Library, and Personalized Organization Tools
Setup (v2.15.0) When setting up a protocol, the app now asks how a dose is measured and only shows the matching units, preventing mix-ups between drug amount and syringe marks. Users can also split a dose across two vials when a single vial doesn't hold enough liquid. The app walks users through drawing
More news about: Peptide Tracker
Sep 08, 2026, 08:00 ET NanoMosaic Joins Mass General Brigham-Led Consortium Awarded ARPA-H GIVE Program to Advance On-Demand Distributed Manufacturing of Genetic Medicines
development and manufacturing and to accelerate the discovery and development of biomarkers for a wide range of applications, including disease diagnosis, drug discovery, and precision medicine.Media ContactsNanoMosaic, Inc.Paul BerningSenior Director, Sales and Business
More news about: NanoMosaic
Sep 08, 2026, 08:00 ET Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress
in lung function, increasingly sensitive CT quantification results may help detect subtle treatment effects and support more efficient, data-informed drug development.These positive results have catalyzed further collaboration between Brainomix and Endeavor BioMedicines, aiming to incorporate quantitative
More news about: Brainomix
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.A supplemental New Drug Application (sNDA) for CAPLYTA® with long-term data evaluating the safety and efficacy of the medication for delayed time to relapse in schizophrenia
More news about: Johnson & Johnson
Sep 08, 2026, 08:00 ET Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Sept. 8, 2026 /PRNewswire/ -- Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation
More news about: Abbott
Sep 08, 2026, 07:45 ET TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
of patients with AML. TuHURA is also leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting MDSCs to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired
More news about: TuHURA Biosciences, Inc.
Sep 08, 2026, 07:05 ET UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc.
alleges that Unicycive failed to properly inspect its third-party vendor's manufacturing facility to ensure it resolved the U.S. Food and Drug Administration's ("FDA") previously noted deficiencies.Investors who suffered significant losses during the Class Period may be eligible to participate
More news about: Robbins LLP
Sep 08, 2026, 07:00 ET Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and
More news about: Compugen Ltd.
Sep 08, 2026, 07:00 ET Israel National Biotech Innovation Center (INBI) Announces Official Launch and the Appointment of Anat Cohen-Dayag, PhD, as Chief Executive Officer of INBI Core
advance an exceptional portfolio of promising Israeli biomedical research programs. It will build a world-class team with deep expertise in early-stage drug development, provide the necessary infrastructure and funding and unlock capital and commercialization opportunities for the next generation of Israeli
More news about: Israel National Biotech Innovation Center
Sep 08, 2026, 06:59 ET Carboxymethylcellulose Calcium Market worth $0.09 billion by 2036 - Exclusive Report by MarketsandMarkets™
oral and topical drug formulations, where carboxymethylcellulose calcium helps improve formulation consistency, viscosity, and product stability. In addition, the growing pharmaceutical manufacturing base across emerging economies is creating opportunities for excipient suppliers as drug production and
More news about: MarketsandMarkets
Sep 08, 2026, 06:45 ET New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgical pain studies
of rigorous clinical development behind TYLENOL® with Naproxen, a new, non-opioid, OTC combination pain relief medicine approved by the U.S. Food and Drug Administration (FDA) in July 2026.
More news about: Kenvue Inc.
Sep 08, 2026, 06:30 ET Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving,
More news about: Caris Life Sciences
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
oral tablets (oral amylin receptor peptide agonist) for the treatment of obesity after recently receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
的口服小分子和長效注射劑項目，ASC36進一步強化了我們的多元化產品管線，以滿足肥胖症及其他代謝疾病患者不斷變化的治療需求。」ASC36是一款利用歌禮專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）技術自主研發的胰澱素受體激動劑多肽。ASC36口服片劑由歌禮利用其專有的口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT）開發並優化而成，該技術用於實現口服多肽遞送。在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7天後，穩態下的絕對口服生物利用度（absolute
More news about: 歌禮製藥有限公司